Orlewska E - Search Results

1

Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries.

Orlewska E, Ancuta I, Anic B, Codrenau C, Damjanov N, Djukic P, Ionescu R, Marinchev L, Nasonov EL, Peets T, Praprotnik S, Rashkov R, Skoupa J, Tlustochowicz W, Tlustochowicz M, Tomsic M, Veldi T, Vojinovic J, Wiland P. Orlewska E, et al. Med Sci Monit. 2011 Apr;17(4):SR1-13. doi: 10.12659/msm.881697. Med Sci Monit. 2011. PMID: 21455121 Free PMC article.

2

Challenges in economic evaluation of new drugs: experience with rituximab in Hungary.

Brodszky V, Orlewska E, Pentek M, Karpati K, Skoupa J, Gulacsi L. Brodszky V, et al. Among authors: orlewska e. Med Sci Monit. 2010 Jan;16(1):SR1-5. Med Sci Monit. 2010. PMID: 20037504

3

The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland.

Orlewska E. Orlewska E. Value Health. 2002 Sep-Oct;5(5):405-21. doi: 10.1046/J.1524-4733.2002.55147.x. Value Health. 2002. PMID: 12201858 Free article.

4

Economic aspects in medical decision-making.

Orlewska E. Orlewska E. Transplant Proc. 2003 May;35(3):1227-9. doi: 10.1016/s0041-1345(03)00200-8. Transplant Proc. 2003. PMID: 12947913 No abstract available.

5

Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries.

Orlewska E, Mierzejewski P. Orlewska E, et al. Value Health. 2004 Jan-Feb;7(1):1-10. doi: 10.1111/j.1524-4733.2004.71257.x. Value Health. 2004. PMID: 14720125 Free article.

6

A prospective study of the financial costs of multiple sclerosis at different stages of the disease.

Orlewska E, Mierzejewski P, Zaborski J, Kruszewska J, Wicha W, Fryze W, Drozdowski W, Skibicka I, Mirowska-Guzel D, Czlonkowski A, Czlonkowska A. Orlewska E, et al. Eur J Neurol. 2005 Jan;12(1):31-9. doi: 10.1111/j.1468-1331.2004.00950.x. Eur J Neurol. 2005. PMID: 15613144

7

Budget-impact analyses: a critical review of published studies.

Orlewska E, Gulácsi L. Orlewska E, et al. Pharmacoeconomics. 2009;27(10):807-27. doi: 10.2165/11313770-000000000-00000. Pharmacoeconomics. 2009. PMID: 19803537 Review.

8

Adherence to biologic DMARD therapies in rheumatoid arthritis.

Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L. Koncz T, et al. Among authors: orlewska e. Expert Opin Biol Ther. 2010 Sep;10(9):1367-78. doi: 10.1517/14712598.2010.510508. Expert Opin Biol Ther. 2010. PMID: 20681888 Review.

9

Cost-effectiveness of somatostatin analogues in the treatment of acromegaly.

Orlewska E, Stępień R, Orlewska K. Orlewska E, et al. Expert Rev Pharmacoecon Outcomes Res. 2019 Feb;19(1):15-25. doi: 10.1080/14737167.2018.1513330. Epub 2018 Sep 3. Expert Rev Pharmacoecon Outcomes Res. 2019. PMID: 30122081 Review.

10

Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective.

Orlewska E, Budaj A, Tereszkowski-Kaminski D. Orlewska E, et al. Pharmacoeconomics. 2003;21(10):737-48. doi: 10.2165/00019053-200321100-00005. Pharmacoeconomics. 2003. PMID: 12828495

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters